Tickers

1. Composite Trajectory Verdict

The income statement carries the most weight for assessing ADUS's financial performance because the business model is driven by revenue growth from acquisitions and organic volume, with margin expansion reflecting operating leverage in a labor-intensive services business.

Composite Trajectory: Improving

Revenue growth is consistent across annual and quarterly periods (23.2% YoY for FY2025, 8.0% YoY for Q2 2026, 7.8% YoY for YTD 2026). Operating margins expanded annually (9.7% vs 8.9%) and quarterly (10.3% vs 9.4%), with net income growing faster than revenue (30.3% annually, 25.2% quarterly). The balance sheet shows significant deleveraging (long-term debt cut from $218.4M to $61.6M over 18 months) and equity growth. Cash generation is mixed: annual operating cash flow was flat, but YTD 2026 operating cash flow more than doubled to $92.4M vs $41.5M, and investing outflows normalized post-acquisition.

2. Red Flags

• Illinois Department on Aging receivable DSO spike: DSO for the largest payor jumped to 55 days at Dec 2025 from 40 days at Dec 2024, though it improved to 27 days by June 2026 (10-K 2025-12-31, MD&A Liquidity; 10-Q 2026-06-30, MD&A Outstanding Accounts Receivable).
• Home health segment contraction: Revenue declined 4.8% YoY in Q2 2026 and 5.9% YoY YTD 2026, with segment operating margin falling from 24.3% to 19.1% (Q2) and 20.5% to 19.0% (YTD) (10-Q 2026-06-30, Results of Operations – Segments).
• Hospice margin compression: Gross margin fell from 47.9% to 44.0% (Q2) and 47.7% to 45.2% (YTD); segment operating margin dropped from 23.8% to 18.8% (Q2) and 23.8% to 20.6% (YTD) (10-Q 2026-06-30, Results of Operations – Segments).
• Goodwill concentration: Goodwill of $996.7M at Dec 2025 represents 91.8% of total equity, with $469.0M in personal care segment alone (10-K 2025-12-31, Consolidated Balance Sheets).
• Recurring acquisition-related adjustments: Acquisition expense appears in Adjusted EBITDA reconciliation for three consecutive years ($8.9M, $14.7M, $6.2M), suggesting acquisitive growth is a persistent feature rather than non-recurring (10-K 2025-12-31, Non-GAAP Financial Measures).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Net service revenues grew 23.2% to $1,422.5M in FY2025 vs FY2024, and 8.0% to $377.4M in Q2 2026 vs Q2 2025. Gross margin held at 32.5% annually and dipped slightly to 32.2% in Q2 2026 from 32.6%. Operating income rose 35.0% annually to $138.6M and 18.4% quarterly to $38.9M, with operating margins expanding to 9.7% (FY2025) and 10.3% (Q2 2026). Net income grew 30.3% annually to $95.9M and 25.2% quarterly to $27.6M. Personal care drove growth (27.2% annually, 10.0% quarterly) while hospice grew modestly (15.1% annually, 3.3% quarterly) and home health declined (-4.8% quarterly).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow was essentially flat at $111.5M in FY2025 vs $116.4M in FY2024, despite 30% net income growth, due to working capital changes. However, YTD 2026 operating cash flow surged to $92.4M vs $41.5M in YTD 2025, driven by receivables timing and payroll/payables timing. Annual investing cash flow normalized to -$32.5M in FY2025 from -$354.6M in FY2024 (Gentiva acquisition). YTD 2026 investing was -$15.2M vs +$0.3M in YTD 2025. Financing cash flow was -$96.3M in FY2025 (net debt repayment) and -$59.2M YTD 2026 (continued debt repayment), compared to +$272.3M in FY2024 (debt draw + equity offering).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total debt decreased from $218.4M at Dec 2024 to $121.0M at Dec 2025 to $61.6M at June 2026. Cash increased from $81.6M at Dec 2025 to $99.6M at June 2026. Total liabilities fell from $442.1M to $352.0M to $308.3M over the same periods. Stockholders' equity grew from $970.5M to $1,085.3M to $1,148.2M. Accounts receivable net declined from $151.7M to $145.1M in H1 2026. The net leverage ratio (implied) improved materially; the company remained in compliance with the 3.75x covenant at both Dec 2025 and June 2026 (10-K 2025-12-31, Liquidity; 10-Q 2026-06-30, Liquidity).

6. Data Gaps

• Full-year 2026 GAAP figures (only YTD and quarterly available)
• Q3 2026 and Q4 2026 results to complete FY2026 trend
• Segment-level cash flow and balance sheet detail
• Breakdown of "acquisition expense" components across periods
• Organic vs. acquisitive revenue growth split for consolidated totals (only same-store % provided for segments)
• Interest coverage ratio calculation (EBIT/interest) for FY2023 to assess trend